Jones Hill Capital LP
13F Reported Value
ⓘ$470.4M
Holdings
29
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Jones Hill Capital LP disclosed 29 positions worth $470.4M in its Form 13F-HR for Q2 2026, led by $BMRN (BIOMARIN PHARMACEUTICAL INC) at 17.4% of the equity portfolio, followed by $GILD and $ARQT. During the quarter the fund opened 15 new positions and exited 12 — including a new stake in $GILD and a full exit from $PCVX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Jones Hill Capital LP’s Form 13F-HR filing with the SEC under CIK 2102314.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 58.2#1,030
Quality
$81.9M1,431,590 sh - 57.4#1,096
Quality
$43.3M343,043 sh - 62.9#675
Quality
$28.6M1,089,701 sh - 40.7
Quality
$28.2M52,545 sh - —
Quality
$26.5M892,621 sh - —
Quality
$25.3M3,655,075 sh - —
Quality
$25.0M1,339,212 sh - —
Quality
$23.4M677,879 sh - 24.0
Quality
$22.2M367,900 sh - 72.5
Quality
$19.4M233,808 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 BIOMARIN PHARMACEUTICAL INC$BMRN | 58.2#1,030 | $81.9M | 1,431,590 |
 GILEAD SCIENCES, INC.$GILD | 57.4#1,096 | $43.3M | 343,043 |
 Arcutis Biotherapeutics, Inc.$ARQT | 62.9#675 | $28.6M | 1,089,701 |
 MADRIGAL PHARMACEUTICALS, INC.$MDGL | 40.7 | $28.2M | 52,545 |
 Bicara Therapeutics Inc.$BCAX | — | $26.5M | 892,621 |
 RELMADA THERAPEUTICS, INC.$RLMD | — | $25.3M | 3,655,075 |
 Trevi Therapeutics, Inc.$TRVI | — | $25.0M | 1,339,212 |
 Pharvaris N.V.$PHVS | — | $23.4M | 677,879 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $22.2M | 367,900 |
 ANI PHARMACEUTICALS INC$ANIP | 72.5 | $19.4M | 233,808 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Jones Hill Capital LP's 29 positions.
Showing top 10 of 29 holdings.
Sector Allocation
Healthcare
$470.4M
Full Holdings — Jones Hill Capital LP (Q2 2026)
All 29 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $81.9M | 17.4% | +13% | 58.2 |
| 2 | $GILD | GILEAD SCIENCES, INC. | $43.3M | 9.2% | NEW | 57.4 |
| 3 | $ARQT | Arcutis Biotherapeutics, Inc. | $28.6M | 6.1% | NEW | 62.9 |
| 4 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $28.2M | 6.0% | NEW | 40.7 |
| 5 | $BCAX | Bicara Therapeutics Inc. | $26.5M | 5.6% | -29% | — |
| 6 | $RLMD | RELMADA THERAPEUTICS, INC. | $25.3M | 5.4% | +966% | — |
| 7 | $TRVI | Trevi Therapeutics, Inc. | $25.0M | 5.3% | +262% | — |
| 8 | $PHVS | Pharvaris N.V. | $23.4M | 5.0% | +306% | — |
| 9 | $XENE | Xenon Pharmaceuticals Inc. | $22.2M | 4.7% | NEW | 24 |
| 10 | $ANIP | ANI PHARMACEUTICALS INC | $19.4M | 4.1% | -27% | 72.5 |
| 11 |  $IMCR | Immunocore Holdings plc | $16.3M | 3.5% | NEW | — |
| 12 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $16.1M | 3.4% | -44% | 8.7 |
| 13 |  $INSM | INSMED Inc | $13.0M | 2.8% | NEW | 39.4 |
| 14 |  $NUVL | Nuvalent, Inc. | $12.2M | 2.6% | -67% | — |
| 15 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $10.1M | 2.1% | -54% | 13.6 |
| 16 |  $ACRS | Aclaris Therapeutics, Inc. | $9.3M | 2.0% | NEW | 12 |
| 17 |  $IMUX | IMMUNIC, INC. | $8.3M | 1.8% | NEW | — |
| 18 |  $ORIC | Oric Pharmaceuticals, Inc. | $8.1M | 1.7% | NEW | — |
| 19 |  $TNXP | Tonix Pharmaceuticals Holding Corp. | $8.0M | 1.7% | +38% | 26.5 |
| 20 |  $SNDX | Syndax Pharmaceuticals Inc | $7.4M | 1.6% | NEW | 33.8 |
| 21 |  $OLMA | Olema Pharmaceuticals, Inc. | $7.2M | 1.5% | NEW | — |
| 22 |  $VIR | Vir Biotechnology, Inc. | $6.7M | 1.4% | -45% | 38.2 |
| 23 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $6.1M | 1.3% | NEW | — |
| 24 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.6M | 1.2% | NEW | 22.6 |
| 25 |  $VRTX | VERTEX PHARMACEUTICALS INC / MA | $5.5M | 1.2% | -90% | 75.4 |
| 26 |  $ELVN | Enliven Therapeutics, Inc. | $2.5M | 0.5% | -92% | — |
| 27 |  $GPCR | Structure Therapeutics Inc. | $2.2M | 0.5% | -60% | — |
| 28 |  $PHAT | Phathom Pharmaceuticals, Inc. | $1.8M | 0.4% | NEW | 40.9 |
| 29 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $174,743 | 0.0% | NEW | — |
New Positions (15)
$GILD GILEAD SCIENCES, INC.$43.3M$ARQT Arcutis Biotherapeutics, Inc.$28.6M$MDGL MADRIGAL PHARMACEUTICALS, INC.$28.2M$XENE Xenon Pharmaceuticals Inc.$22.2M$IMCR Immunocore Holdings plc$16.3M$INSM INSMED Inc$13.0M$ACRS Aclaris Therapeutics, Inc.$9.3M$IMUX IMMUNIC, INC.$8.3M$ORIC Oric Pharmaceuticals, Inc.$8.1M$SNDX Syndax Pharmaceuticals Inc$7.4M$OLMA Olema Pharmaceuticals, Inc.$7.2M$CRBP Corbus Pharmaceuticals Holdings, Inc.$6.1M$DNTH Dianthus Therapeutics, Inc. /DE/$5.6M$PHAT Phathom Pharmaceuticals, Inc.$1.8M$ACHV ACHIEVE LIFE SCIENCES, INC.$174,743Exited Positions (12)
$PCVX Vaxcyte, Inc.
$TERN Terns Pharmaceuticals, Inc.
$RARE Ultragenyx Pharmaceutical Inc.
$ARGX ARGENX SE
$FULC Fulcrum Therapeutics, Inc.
$NUVB Nuvation Bio Inc.
$ORKA Oruka Therapeutics, Inc.
$CTNM Contineum Therapeutics, Inc.
$MANE Veradermics, Inc
$TRDA Entrada Therapeutics, Inc.
$SLN Silence Therapeutics plc
$AVBP ArriVent BioPharma, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Jones Hill Capital LP including:
Track Jones Hill Capital LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Jones Hill Capital LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Jones Hill Capital LP
13F Pro is an AI hedge fund tracker and stock research platform. For Jones Hill Capital LP (SEC CIK: 2102314), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Jones Hill Capital LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.